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Abstract
Background: Reproductive dysfunction in the diabetic female rat is associated with altered folliculogenesis and
steroidogenesis. However, the molecular mechanisms involved in the reduction of steroid production have not
been described. Adiponectin is an adipocytokine that has insulin-sensitizing actions including stimulation of glucose
uptake in muscle and suppression of glucose production in liver. Adiponectin acts via two receptor isoforms –
AdipoR1 and AdipoR2 – that are regulated by hyperglycaemia and hyperinsulinaemia in liver and muscle. We have
recently identified AdipoR1 and AdipoR2 in rat ovary. However, their regulation in ovaries of diabetic female rat
remains to be elucidated.
Methods: We incubated rat primary granulosa cells in vitro with high concentrations of glucose (5 or 10 g/l) +
or - FSH (10-8 M) or IGF-1 (10-8 M), and we studied the ovaries of streptozotocin-induced diabetic rats (STZ)
in vivo. The levels of oestradiol and progesterone in culture medium and serum were measured by RIA. We used
immunoblotting to assay key steroidogenesis factors (3beta HSD, p450scc, p450 aromatase, StAR), and
adiponectin receptors and various elements of signalling pathways (MAPK ERK1/2 and AMPK) in vivo and in vitro.
We also determined cell proliferation by [3H] thymidine incorporation.
Results: Glucose (5 or 10 g/l) impaired the in vitro production in rat granulosa cells of both progesterone and
oestradiol in the basal state and in response to FSH and IGF-1 without affecting cell proliferation and viability. This
was associated with substantial reductions in the amounts of 3beta HSD, p450scc, p450 aromatase and StAR
proteins and MAPK ERK1/2 phosphorylation. In contrast, glucose did not affect the abundance of AdipoR1 or
AdipoR2 proteins. In vivo, as expected, STZ treatment of rats caused hyperglycaemia and insulin, adiponectin and
resistin deficiencies. Plasma progesterone and oestradiol levels were also reduced in STZ rats. However, the
amounts of 3beta HSD and p450 aromatase were the same in STZ rat ovary and controls, and the amounts of
StAR and p450scc were higher. Streptozotocin treatment did not affect adiponectin receptors in rat ovary but it
increased AMPK phosphorylation without affecting MAPK ERK1/2 phosphorylation.
Conclusion: High levels of glucose decrease progesterone and oestradiol production in primary rat granulosa
cells and in STZ-treated rats. However, the mechanism that leads to reduced ovarian steroid production seems
to be different. Furthermore, adiponectin receptors in ovarian cells are not regulated by glucose.
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Background
Diabetes is associated with increased risk of various dis-
eases including cardiovascular disorders, and is also
linked to reproductive problems such as impaired follicu-
logenesis and steroidogenesis, anovulation, and sponta-
neous abortions [1-6]. Although several studies have
shown altered ovarian function in association with diabe-
tes, the molecular alterations in ovarian steroid metabo-
lism that could explain these reproductive dysfunctions
remain to be elucidated. Cholesterol metabolism is pro-
foundly altered in the diabetic condition [7,8], and cho-
lesterol is the essential precursor molecule in the synthesis
of steroid hormones. Follicular development and ovula-
tion are dependent on proliferative and differentiation
changes in granulosa cells (GCs) and thecal cells, which
undergo steroidogenesis upon stimulation with gonado-
tropins and intraovarian cytokines [9]. For example, FSH
(Follicle Stimulating Hormone) and IGF-1 (Insulin-like
Growth Factor-1) stimulate the expression of steroidog-
enic enzymes including the cholesterol side-chain cleav-
age cytochrome p450 (p450scc), 3β-hydroxysteroid
dehydrogenase (3βHSD), cytochrome p450 aromatase
(p450 aromatase) and the steroidogenic acute regulatory
protein (StAR), which is a protein that participates in the
transport of cholesterol from the mitochondrial outer
membrane to the inner membrane [10]. The MAPK ERK1/
2 signalling pathway has been reported to be involved in
the regulation of steroidogenesis in granulosa cells.
Indeed, some studies suggest that activation of MAPK
ERK1/2 is required for promoting steroidogenesis and
steroidogenic gene expression in granulosa cells [11,12].
Furthermore, we have recently shown that the activation
of AMPK, a key regulator of cellular energy homeostasis,
reduces progesterone secretion through inhibition of the
MAPK ERK1/2 signalling pathway in rat and bovine gran-
ulosa cells [13,14]. However, it remains to be determined
whether diabetes is associated with abnormalities in the
abundance of ovarian p450scc, 3βHSD, StAR, p450 aro-
matase or in MAPK ERK1/2 and AMPK phosphorylations.
Alterations of glucose concentrations can profoundly
affect some reproductive process. For example, glucose is
required for hormone-induced maturation, but under the
appropriate culture conditions, elevated levels of glucose
can suppress maturation [15]. However, these effects can
be reversed by insulin [15]. Adiponectin is an adipokine
that has insulin sensitizing actions including stimulation
of glucose uptake in skeletal muscle and suppression of
glucose production in liver [16]. Hence, adiponectin has
attracted great interest as an antidiabetic agent. Adiponec-
tin acts via two receptor isoforms, AdipoR1 and AdipoR2,
which have different tissue distributions [17]. Expression
of AdipoR isoforms can be regulated by hyperinsulinae-
mia and hyperglycaemia [18]. Adiponectin is a key adi-
pokine in the regulation of energy metabolism; however,
it is also able to control some reproductive functions.
Recently, the adiponectin system (adiponectin, AdipoR1
and AdipoR2) was described in rat and human hypotha-
lamus [19] and pituitary [20]. In rat primary pituitary
cells, recombinant adiponectin regulates GnRH receptor
expression [20]. In mouse LβT2 gonadotrope cells and in
rat pituitary cells, recombinant adiponectin inhibits LH
secretion [20,21]. Moreover, adiponectin and AdipoR2
are expressed in rat and human placenta and rat placental
adiponectin mRNA increases in abundance during preg-
nancy whereas AdipoR2 has the opposite pattern [22].
Adiponectin and its receptors are also present in ovary of
various species including pig [23,24], chicken [25,26] and
rat [27]. Ledoux et al. reported that recombinant adi-
ponectin has a direct effect on gene expression in porcine
follicular cells associated with ovarian follicle remodel-
ling [24]. In recent work, our group showed that adi-
ponectin is mainly expressed in rat theca-interstitial cells
and could exert paracrine effects on the steroidogenesis of
granulosa cells [27]. The expression of the adiponectin
system in insulin target tissues (muscle, adipose tissue
and liver) in human and animal diabetic models has been
studied [27-29]. However, the expression of the adiponec-
tin system in reproductive tissues in diabetic animals has
not been explored.
We report an investigation of ovarian steroid production
and the protein levels of key factors involved in steroido-
genesis in two conditions: in primary rat granulosa cells in
the presence of high glucose concentrations; and in strep-
tozotocin-treated female rats. In these conditions, we also
assayed adiponectin receptor proteins in ovarian cells.
Methods
Hormones and reagents
Purified ovine FSH-20 (oFSH) (lot no.AFP-7028D, 4453
IU/mg, with an FSH activity = 175 times the activity of
oFSH-S1) used for culture treatment was a gift from
NIDDK, National Hormone Pituitary Program, Bethesda,
MD, USA. Recombinant human insulin-like growth fac-
tor-I (IGF-I) was from Sigma (St Louis, MO, USA). Recom-
binant human adiponectin produced in the NSO
mammalian cell system was obtained from R&D (Lille,
France). Glucose was from VWR (Fontenay sous bois,
France).
Antibodies
Rabbit polyclonal antibodies to adiponectin receptor 2
(4–39) and adiponectin receptor 1 (41–65) were from
Phoenix Pharmaceuticals Inc. (Belmont, CA, USA). Rabbit
polyclonal antibodies to phospho-ERK1/2 (Thr202/
Tyr204), and phospho-AMPK alpha Thr172 were pur-
chased from New England Biolabs Inc (Beverly, MA). Rab-
bit polyclonal antibodies to AMPKα1 were obtained from
Upstate Biotechnology Inc (Lake, Placid, NY, USA). Rab-Reproductive Biology and Endocrinology 2008, 6:11 http://www.rbej.com/content/6/1/11
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bit polyclonal antibodies to ERK2 (C14) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse
monoclonal antibody to vinculin was obtained from
Sigma (St. Louis, MO, USA). Rabbit polyclonal antibodies
against p450scc, StAR and 3βHSD were generously pro-
vided by Dr. Dale Buchanan Hales (University of Illinois,
Chicago, USA) and Dr. Van Luu-The (CHUL Research
Center and Laval University, Canada), respectively. Mouse
monoclonal antibody against p450 aromatase was pur-
chased from Serotec (Varilhes, France). All antibodies
were used at 1/1000 dilution for western blotting.
Animals and experimental procedures
All procedures were approved by the Agricultural Agency
and the Scientific Research Agency and conducted in
accordance with the guidelines for Care and Use of Agri-
cultural Animals in Agricultural Research and Teaching.
Eight week-old female Wistar rats (n = 18) were purchased
from Janvier Laboratories (France). They were housed
with controlled temperature and photoperiod (10 h dark-
ness, 14 h light, light on from 0600–2000 h). The animals
had ad libitum access to food and water. Diabetes was
induced in one group of rats (n = 12) by an intraperito-
neal injection of 1 ml of 50 mM sodium citrate solution
(pH 4.5) containing streptozotocin (STZ, 55 mg/kg body
weight). Control female rats (C, n = 6) were injected with
50 mM sodium citrate solution (pH 4.5). One week after
injection, plasma glucose levels were checked for each ani-
mal and diabetes was confirmed (plasma glucose level >3
g/l). Then, control and STZ-treated rats were killed at die-
strus stage. One sample of blood was taken and then tis-
sues (ovaries, leg muscles and liver) were removed and
frozen for western blotting.
Isolation and culture of rat granulosa cells
Immature female Wistar rats (21 days) were injected sub-
cutaneously with DES (diethylstilbestrol, 1 mg/day) every
day for three days to increase the amount of granulosa
cells as previously described [14,30]. On the third day of
DES treatment the animals were killed and the ovaries
removed aseptically and transferred to culture medium.
Granulosa cells were harvested by puncturing the follicles
allowing expulsion of the cells. Cells were recovered by
centrifugation, washed with fresh medium and counted in
a hemocytometer. The culture medium used was McCoy's
5A supplemented with 20 mmol/L Hepes, penicillin (100
U/ml), streptomycin (100 mg/l), L-glutamine (3 mmol/
l), 0.1% BSA, 0.1 µmol/l androstenedione, 5 mg/l trans-
ferrin, 20 µg/l selenium and 5% FBS. The cells were first
cultured for 48 h with no other treatment and then incu-
bated in DMEM medium without glucose and serum but
containing penicillin (100 U/ml), streptomycin (100 mg/
l), L-glutamine (3 mmol/l) and 0.1 µmol/l androstenedi-
one with or without test reagents (glucose, FSH, IGF-1) for
the appropriate time as indicated in the legend of the fig-
ures. All cultures were performed under a water-saturated
atmosphere of 95% air/5% CO2 at 37°C.
Western blotting
Lysates of granulosa cells or tissue were prepared on ice
with an Ultraturax homogenizer in lysis buffer (10 mM
Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.5% Igepal) containing various protease inhibitors (2
mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin) and
phosphatase inhibitors [100 mM sodium fluoride, 10
mM sodium pyrophosphate, 2 mM sodium orthovanad-
ate, (Sigma, l'Isle d'Abeau Chesnes, France)]. Lysates were
centrifuged at 13,000 g for 20 min at 4°C, and the protein
concentration in the supernatants was determined using a
colorimetric assay (kit BC Assay, Uptima Interchim,
Montluçon, France).
Cell extracts were subjected to electrophoresis on 10%
(w:v) SDS-polyacrylamide gel under reducing conditions.
The proteins were then electrotransferred onto nitrocellu-
lose membranes (Schleicher and Schuell, Ecquevilly,
France) for 2 h. The membranes were incubated for 1 h at
room temperature with Tris-buffered saline (TBS, 2 mM
Tris-HCl, pH 8.0, 15 mM NaCl, pH 7.6), containing 5%
nonfat dry milk powder (NFDMP) and 0.1% Tween-20 to
saturate non-specific sites. Then, the membranes were
incubated overnight at 4°C with appropriate antibodies
(final dilution 1:1,000), in TBS containing 0.1% Tween-
20 and 5% NFDMP. They were washed in TBS-0.1%
Tween-20, incubated for 2 h at room temperature with a
horseradish peroxidase-conjugated anti-rabbit or anti-
mouse IgG (final dilution 1:10,000; Diagnostic Pasteur,
Marnes-la-Coquette, France) in TBS, 0.1% Tween-20 5%
NFDMP, and washed again in TBS-0.1% Tween-20. The
signal was detected by ECL (enhanced chemilumines-
cence, Amersham Pharmacia Biotech, Orsay, France).
The films were analyzed and signals quantified with the
software MacBas V2.52 (Fuji PhotoFilm, USA, Inc.). The
results are expressed as the signal intensity in arbitrary
units after normalization to the signal for vinculin, used
as an internal standard, and each value reported corre-
sponds to the means of three independent experiments.
Thymidine incorporation into granulosa cells
Granulosa cells (2 × 105 viable cells/500 µl) were cultured
in 24-well dishes in McCoy's 5A medium containing 10%
FBS for 48 h and were then serum starved for 24 h in
DMEM medium without glucose: then 1 µCi/µl of [3H]
thymidine (Amersham Life Science, Arlington Heights,
IL) was added in the presence or absence of various con-
centrations of glucose and/or FSH (10-8M) and IGF-1 (10-
8 M). Cultures were maintained at 37°C under 5% CO2 in
air. After 24 h of culture, excess of thymidine was removed
by washing twice with phosphate-buffered saline (PBS),Reproductive Biology and Endocrinology 2008, 6:11 http://www.rbej.com/content/6/1/11
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and the samples were fixed with cold trichloroacetic acid
50% for 15 min and lysed by addition of 0.5 N NaOH.
The radioactivity was determined by addition of scintilla-
tion fluid (Packard Bioscience) and counting in a β-pho-
tomultiplier.
Progesterone and oestradiol radioimmunoassay
The concentration of progesterone (P) and oestradiol (E2)
in the culture medium of granulosa cells was measured
after 48 h of culture by a radioimmunoassay protocol as
previously described [31-33] and adapted to measure ster-
oids in cell culture media. The limit of detection of P was
12 pg/tube (60 pg/well) and the intra- and interassay coef-
ficients of variation were less than 10% and 11%, respec-
tively. The limit of detection of E2 was 1.5 pg/tube (7.5
pg/well) and the intra-and interassay coefficients of varia-
tion were less than 7% and 9%, respectively. Results are
expressed as the amount of steroids secreted per 48 h per
100 µg of protein, and values reported are means ± SE of
three cultures of granulosa cells. For each culture, about
30 to 40 rats were used and each condition (FSH, IGF-1,
glucose alone or combined with IGF-1 or FSH) was ana-
lyzed four times independently.
After extraction of steroids from serum, the concentration
of progesterone was measured by the RIA method as pre-
viously described [34]. The oestradiol concentration in
the serum was measured with a RIA KIT (DIASORIN,
Antony, France).
Glucose, adiponectin, resistin and insulin plasma levels
Plasma glucose was assayed by the glucose oxidase
method (Glucose Beckman Analyser 2, Beckman, Palo
Alto, CA). Plasma adiponectin and resistin were assayed
with a rat adiponectin ELISA kit (Phoenix Pharmaceuti-
cals, Inc, Belmont, CA, USA) and a rat resistin ELISA kit
(BioVendor laboratory Medicine, Inc, Heidelberg, Ger-
many), respectively. Serum insulin levels were determined
using a rat insulin ELISA kit (Mercodia AB, Uppsala, Swe-
den).
Statistical analysis
All experimental data are presented as the mean ± SE. One
t-test (for comparison of two means, Control and STZ) or
one-way analysis of variance (ANOVA) (for comparison
of various means) were used to test differences; if ANOVA
revealed significant effects, the means were compared by
Newman's test, with P < 0.05 considered significant.
Results
Effect of glucose on basal and FSH- or IGF-1-stimulated 
oestradiol and progesterone production in rat granulosa 
cells
The effects of glucose treatment on steroidogenesis in rat
granulosa cells were first examined in incubations con-
taining various concentrations of glucose for 48 h. Con-
centrations of glucose greater than 5 g/l were found to
inhibit the syntheses of progesterone and oestradiol (data
not shown). We also determined whether glucose (10 g/l)
affected the production of progesterone and oestradiol in
response to FSH or IGF-1. In the presence of FSH (10-8M),
glucose (10 g/l, 48 h) decreased the secretion of progester-
one (p < 0.01) and oestradiol (p < 0.01) by a factor of
about five (Fig. 1A and 1B). In the presence of IGF-1 (10-
8M), glucose (10 g/l, 48 h) decreased the secretion proges-
terone (p < 0.01) and oestradiol (p < 0.01) by a factor of
about three (Fig. 1A and 1B). Similar results were
obtained with a lower dose of glucose (5 g/l, data not
shown). Thus, a high glucose concentration (5 or 10 g/l)
decreased both basal and FSH-or IGF-1-stimulated pro-
gesterone and oestradiol production in rat granulosa cells.
We then investigated whether this inhibitory effect of glu-
cose on the production of both progesterone and oestra-
diol resulted from the production of smaller amounts of
the three key enzymes in steroidogenesis (3βHSD,
p450scc and p450 aromatase) and/or of StAR, a major
cholesterol carrier. Glucose treatment (10 g/l, 48 h) in the
presence of FSH (10-8M) decreased production of 3βHSD
(Fig. 2A, p < 0.001) and p450scc (Fig. 2B, p < 0.001) by a
factor of about seven, halved the production of StAR (Fig.
2C, 0.05) and reduced by three-fold the production of
p450 aromatase (Fig. 2D, p < 0.001), relative to the values
in the presence of FSH without glucose. In the presence of
IGF-1 (10-8M), glucose decreased the amounts of the three
key enzymes in steroidogenesis and StAR by a factor of
three relative to IGF-1 treatment without glucose (Fig. 2A
to D, p < 0.05). Similar results were obtained with a lower
glucose concentration (5 g/l, data not shown).
In the basal state (no FSH or IGF-1), glucose treatment (10
g/l, 48 h) only halved the production of 3βHSD, StAR and
p450 aromatase (Fig. 2A, C and 2D, p < 0.05) but did not
affect the amount of p450scc protein (Fig. 2B). Thus, the
decrease in FSH- or IGF-1-induced progesterone and
oestradiol secretions in response to glucose treatment
appears to be caused by a reduction in the amounts of the
3βHSD, p450scc, StAR and p450 aromatase proteins. The
inhibition of basal progesterone and oestradiol secretions
in response to glucose could be the result of a reduction in
production of the 3βHSD, StAR and p450 aromatase pro-
teins.
Effects of glucose on granulosa cell proliferation and 
viability
We investigated whether the dose of glucose used (5 or 10
g/l) affected the number of granulosa cells in culture,
either by induction of mitosis or by altering the cell viabil-
ity. [3H]-thymidine incorporation by granulosa cells
treated with 10 g/l glucose was determined after 24 h ofReproductive Biology and Endocrinology 2008, 6:11 http://www.rbej.com/content/6/1/11
Page 5 of 14
(page number not for citation purposes)
culture in the presence or in the absence of FSH (10-8 M)
or IGF-1 (10-8 M). As expected, FSH and IGF-1 treatment
significantly increased [3H]-thymidine incorporation
(data not shown). However, glucose treatment (either 5 or
10 g/l) did not affect cell proliferation or cell number
(data not shown). Glucose (5 or 10 g/l) had no effect on
the cell viability in the absence or in the presence of FSH
and IGF-1 as assessed by staining with Trypan blue (data
not shown).
Effects of glucose treatment on the MAPK ERK1/2 and 
AMPK phosphorylation and on the adiponectin receptor 
expression in rat granulosa cells
We examined whether the inhibitory effect of glucose on
progesterone and oestradiol production was associated
with a variation in the phosphorylation of MAPK ERK1/2
and AMPK. These kinases have been implicated in the reg-
ulation of steroidogenesis [11,13]. We analysed the pat-
tern of MAPK ERK1/2 phosphorylation in cells incubated
with 10 g/l glucose for various times (0, 5, 10, 30, 60, 120
min, Fig. 3A), or with 10 g/l glucose for 48 h in the pres-
ence or absence of FSH (10-8M) or IGF-1 (10-8M, Fig. 3B).
MAPK ERK1/2 phosphorylation was significantly reduced
after 120 min of treatment with 10 g/l glucose (p < 0.05,
Fig. 3A). It was also decreased in the basal and FSH-or
IGF-1-stimulated conditions used for assaying progester-
one and oestradiol production (48 h of treatment with 10
g/l glucose in serum-free medium, p < 0.05, Fig. 3B). Sim-
ilar results were obtained with a lower glucose concentra-
tion (5 g/l, data not shown). We also determined
phosphorylation of Thr172 in AMPK in similar condi-
tions (effect of glucose in the short and long term); glu-
cose (5 or 10 g/l) had no effect on AMPK phosphorylation
(data not shown). We also investigated the effect of a high
concentration of glucose (10 g/l) on the amounts of
AdipoR1 and AdipoR2 (the adiponectin receptors) in rat
granulosa cells and we detected no significant effect (data
not shown).
Effect of glucose treatment on basal and FSH- or IGF-1-stimulated progesterone and oestradiol secretions by rat granulosa  cells Figure 1
Effect of glucose treatment on basal and FSH- or IGF-1-stimulated progesterone and oestradiol secretions by 
rat granulosa cells. Granulosa cells from immature rats were cultured for 48 h in medium with serum and then in serum-
free medium in the absence or in the presence of 10 g/l glucose ± 10-8 M FSH or 10-8 M IGF-1 for another 48 h (A and B) as 
described in Materials and Methods. The culture medium was then collected and assayed for progesterone (A) and oestradiol 
(B) by RIA. Results are means ± SE for three groups of granulosa cells. Each group of granulosa cells was obtained from about 
30 rats. Bars with different letters are significantly different (p < 0.05). The letter "a" indicates values which are not significantly 
different from control (without FSH or IGF-1 and glucose).
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Effect of glucose treatment on the amounts of the 3βHSD, p450scc, StAR and p450 aromatase proteins in rat granulosa cells Figure 2
Effect of glucose treatment on the amounts of the 3βHSD, p450scc, StAR and p450 aromatase proteins in rat 
granulosa cells. Protein extracts from rat granulosa cells cultured for 48 h in the absence or in the presence of 10 g/l glucose 
± 10-8 M FSH or 10-8 M IGF-1 were subjected to SDS-PAGE as described in Materials and Methods. The membranes were incu-
bated with antibodies raised against the 3βHSD (A), p450scc (B), StAR (C) and p450 aromatase (D) proteins. Equal protein 
loading was verified by reprobing membranes with an anti-vinculin antibody. Results are representative of at least three inde-
pendent experiments. Blots were quantified and the 3βHSD, p450scc, StAR and p450 aromatase to Vinculin ratios are shown. 
The results are expressed as means ± SE. Bars with different letters are significantly different (p < 0.05). The letter "a" indicates 
values which are not significantly different from control (without FSH or IGF-1 and glucose).
Glucose
0
0.5
1.0
1.5
2.0
2.5
3.0
a
d
a,b
b
c
a,b
A.
C.
B.
D.
3 HSD
Vinculin
kDa
110
42
FSH
IGF-1
110
55
Vinculin
p450 scc kDa
StAR
110
31
kDa
Vinculin
110
55
kDa p450 aromatase
Vinculin
Glucose
a
c
a
a
b
a
FSH
IGF-1
Glucose
a
d
a,b
b
c
d
FSH
IGF-1
Glucose
a
d
a,b
b
c
a,b
FSH
IGF-1
R
a
t
i
o
 
3
H
S
D
/
V
i
n
c
u
l
i
n
R
a
t
i
o
 
p
4
5
0
s
c
c
/
V
i
n
c
u
l
i
n
R
a
t
i
o
 
S
t
A
R
/
V
i
n
c
u
l
i
n
R
a
t
i
o
 
p
4
5
0
 
a
r
o
m
a
t
a
s
e
/
V
i
n
c
u
l
i
n
0
0.5
1.0
1.5
2.0
2.5
3.0
0
0.5
1.0
1.5
2.0
2.5
3.0
0
0.5
1.0
1.5
2.0
2.5
3.0Reproductive Biology and Endocrinology 2008, 6:11 http://www.rbej.com/content/6/1/11
Page 7 of 14
(page number not for citation purposes)
Effect of glucose treatment on MAPK ERK1/2 phosphorylation in rat granulosa cells Figure 3
Effect of glucose treatment on MAPK ERK1/2 phosphorylation in rat granulosa cells. Granulosa cell lysates were 
prepared from cells incubated with 10 g/l glucose for various times: 0, 5, 10, 30, 60 or 120 min (A) or with 10 g/l glucose for 48 
h in the presence or absence of FSH (10-8M) or IGF-1 (10-8M). Lysates (50 µg) were resolved by SDS-PAGE, transferred to 
nitrocellulose membrane, and probed with anti-phospho-MAPK ERK1/2 and then with anti-ERK2 antibodies. Representative 
blots from three independent experiments are shown. Blots were quantified and the phosphorylated MAPK ERK1/2/ERK2 pro-
tein ratio is shown. The results are represented as means ± SE. Bars with different letters are significantly different (p < 0.05). 
The letter "a" indicates values which are not significantly different from control (without FSH or IGF-1 and glucose).
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Table 1: Body weight and plasma glucose levels of rats before and after streptozotocin treatment.
Before treatment After treatment
Body weight (g) Plasma Glucose (g/l) Body weight (g) Plasma Glucose (g/l)
Control 179 ± 4 1.20 ± 0.06 230 ± 5 1.1 ± 0.05a
Streptozotocin 173 ± 5 1.10 ± 0.02 215 ± 6 4.1 ± 0.11b
p < 0.05, different letters indicate significant difference between control and streptozotocin animals.Reproductive Biology and Endocrinology 2008, 6:11 http://www.rbej.com/content/6/1/11
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Glucose, insulin, progesterone and oestradiol plasma levels 
in control and STZ-treated rats
We next studied the steroid production in vivo in strepto-
zotocin-induced diabetic mature female rats. The body
weight and plasma glucose levels of control and STZ-
treated rats are shown in Table 1. STZ treatment did not
alter the body weight whereas it significantly increased the
plasma glucose concentrations (glycaemia > 4 g/l, p <
0.0001) to higher than that in control rats (Table 1, Fig.
4A). As expected, serum insulin levels were much lower in
STZ-treated rats than in control rats (Fig. 4B, p < 0.001).
Progesterone (Fig. 4C, p < 0.001) and oestradiol (Fig. 4D,
p < 0.05) concentrations in plasma were also significantly
lower in STZ-treated than control animals.
3βHSD, p450scc, StAR and p450 aromatase in control and 
STZ-treated rat ovaries
To examine possible alterations in the key proteins
required for progesterone and oestradiol production, we
used western-blot analysis of ovarian tissue. There was no
significant difference in the amounts of 3βHSD or p450
aromatase in control and STZ-treated rats (Fig. 5A and
5D). In contrast, there was significantly more p450scc (p
< 0.001) and StAR (p < 0.05) in STZ-treated animals than
in control rats (Fig. 5B and 5C).
Effect of STZ treatment on the plasma levels of 
adiponectin and resistin (A) and on the amounts of 
AdipoR1 and AdipoR2 in rat ovary (B), muscle (C) and liver 
(D)
The concentrations of plasma adiponectin and resistin
were significantly lower in STZ-treated rats than in control
rats (Fig. 6A). We next assayed the adiponectin receptors
in ovary and, as controls in muscle and liver, from control
and STZ-treated rats. The amounts of AdipoR1 and
AdipoR2 were similar in the ovaries of control and STZ-
treated rats (Fig. 6B). STZ treatment did not alter AdipoR1
protein abundance in muscle, but it decreased that of
AdipoR2 (p < 0.1, Fig. 6C). AdipoR2 is the only receptor
detectable in liver, and was unaffected in this tissue by STZ
treatment (Fig. 6D).
Effects of STZ treatment on the MAPK ERK1/2 and AMPK 
phosphorylation in rat ovary
We also analyzed the activation of various signalling path-
ways, including MAPK ERK1/2 and AMPK, involved in
steroidogenesis in rat granulosa cells [11,13]. In ovary,
AMPK phosphorylation was increased by STZ treatment
(Fig. 7A, p < 0.001) whereas the treatment had no effect
on MAPK ERK1/2 phosphorylation (data not shown). In
muscle, phosphorylation of both AMPK and MAPK ERK
1/2 were increased by STZ treatment (p < 0.05, Fig. 7B). In
contrast, MAPK ERK 1/2 phosphorylation in the liver was
strongly reduced by STZ treatment (p < 0.001, Fig. 7C)
whereas AMPK phosphorylation was unchanged (data
not shown).
Discussion
We investigated the impact of hyperglycaemia on steroid
production by rat ovarian cells. We report that high con-
centrations of glucose (5 or 10 g/l) decreased both proges-
terone and oestradiol production by rat primary
granulosa cells in vitro, in both the basal state and in
response to FSH or IGF-1. This inhibitory effect was asso-
ciated with a reduction in the amounts of 3βHSD,
p450scc, StAR and p450 aromatase and of MAPK ERK1/2
phosphorylation. In contrast, AMPK phosphorylation was
not affected by high levels of glucose. We studied the ster-
oidogenesis in vivo, in ovaries of the STZ-treated rats. The
streptozotocin treatment significantly decreased plasma
concentrations of progesterone and oestradiol. Curiously,
this was associated with an increase in the amounts of
p450scc and StAR proteins in the ovaries of STZ-treated
rats whereas the amounts of 3βHSD and p450 aromatase
proteins were similar in STZ-treated and control rats. Fur-
thermore, AMPK phosphorylation was increased in STZ-
Plasma glucose (A), insulin (B), progesterone (C) and oestra- diol (D) concentrations in the control (n = 6) and STZ- treated rats (n = 12) Figure 4
Plasma glucose (A), insulin (B), progesterone (C) and 
oestradiol (D) concentrations in the control (n = 6) 
and STZ-treated rats (n = 12). Plasma glucose was 
assayed by the glucose oxidase method. Plasma insulin con-
centrations were determined by ELISA and plasma proges-
terone and oestradiol were assayed by RIA. C: control; STZ: 
streptozotocin. *p < 0.05, ***p < 0.001
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Effect of STZ treatment on the amounts of the 3βHSD, p450scc, StAR and p450 aromatase proteins in rat ovarian cells Figure 5
Effect of STZ treatment on the amounts of the 3βHSD, p450scc, StAR and p450 aromatase proteins in rat 
ovarian cells. Protein extracts of ovaries from control and STZ-treated rats were subjected to SDS-PAGE as described in 
Materials and Methods. The membranes were incubated with antibodies raised against the 3βHSD (A), p450scc (B), StAR (C) 
and p450 aromatase (D) proteins. Equal protein loading was verified by reprobing membrane with an anti-Vinculin antibody. 
Blots were quantified and the 3βHSD, p450scc, StAR and p450 aromatase/Vinculin ratios are shown. Data are shown as means 
± SE, with n = 6 for the control group and n = 12 for the STZ-treated group. *p < 0.05, *p < 0.001.
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Effect of STZ treatment on the plasma levels of adiponectin and resistin (A) and on the protein levels of AdipoR1 and AdipoR2  in rat ovary (B), muscle (C) and liver (D) Figure 6
Effect of STZ treatment on the plasma levels of adiponectin and resistin (A) and on the protein levels of 
AdipoR1 and AdipoR2 in rat ovary (B), muscle (C) and liver (D). A.A. Plasma adiponectin and resistin concentrations 
were determined by ELISA. C: control; STZ: streptozotocin. *p < 0.05, ***p < 0.001. B, C and D. Lysates (50 µg) of ovary (B), 
muscle (C) and liver (D) from control and STZ-treated rats were resolved by SDS-PAGE, transferred to nitrocellulose mem-
brane, and probed with anti-AdipoR1 or anti-AdipoR2 antibodies. Equal protein loading was verified by reprobing the mem-
brane with an anti-Vinculin antibody. Blots were quantified and the AdipoR1, AdipoR2/vinculin ratios are shown. Data are 
shown as means ± SE, with n = 6 for the control group and n = 12 for the STZ-treated group. *p < 0.05, *p < 0.001.
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Effect of STZ treatment on the phosphorylation levels of AMPK and MAPK ERK1/2 in rat ovary (A), muscle (B) and liver (C) Figure 7
Effect of STZ treatment on the phosphorylation levels of AMPK and MAPK ERK1/2 in rat ovary (A), muscle 
(B) and liver (C). Lysates (50 µg) of ovary, muscle and liver from control and STZ-treated rats were resolved by SDS-PAGE, 
transferred to nitrocellulose membrane, and probed with anti-phospho-AMPK, phospho-MAPK ERK1/2 and then with anti-
AMPKα1 and anti-ERK2 antibodies, respectively. Blots were quantified and the phosphorylated protein/total protein ratio is 
shown. Data are shown as means ± SE, with n = 6 for the control group and n = 12 for the STZ-treated group. *p < 0.05, *p < 
0.001.
pAMPK
AMPK 1
0
0.5
1
1.5
2
2.5
3
A. Ovary
CS T Z
***
B. Muscle
pAMPK
AMPK 1
0
0.4
0.8
1.2
1.6
pERK1/2
ERK2
0
0.4
0.8
1.2
1.6
R
a
t
i
o
 
p
A
M
P
K
/
A
M
P
K
C. Liver
0
0.4
0.8
1.2
1.6
pERK1/2
ERK2
CS T Z CS T Z CS T Z
*** * *
R
a
t
i
o
 
p
A
M
P
K
/
A
M
P
K
R
a
t
i
o
 
p
E
R
K
1
/
2
/
E
R
K
2
R
a
t
i
o
 
p
E
R
K
1
/
2
/
E
R
K
2Reproductive Biology and Endocrinology 2008, 6:11 http://www.rbej.com/content/6/1/11
Page 12 of 14
(page number not for citation purposes)
treated rat ovary whereas the streptozotocin treatment had
no effect on MAPK ERK1/2 phosphorylation. We also
observed that the abundance of adiponectin receptors was
not affected by supra-physiological levels of glucose either
in vitro in rat granulosa cells or in vivo in ovaries of STZ-
treated rats. Thus, glucose seems to be involved in a series
of metabolic pathways that collectively contribute to nor-
mal ovarian steroidogenesis.
In the present study, we have shown that glucose treat-
ment decreases basal and FSH-or IGF-1-stimulated steroid
production in vitro in rat granulosa cells. Furthermore,
this result was associated to a reduction in MAPK ERK1/2
phosphorylation. However, the dose of glucose used in
our study is high (5 or 10 g/l), corresponding to supra-
physiological levels. There are conflicting reports concern-
ing the involvement of MAPK ERK1/2 in the regulation of
steroidogenesis in various steroid-producing cells, proba-
bly because different species (rodents and humans) and
different culture systems have been used in various stud-
ies. Consistent with our findings presented here, studies
in rats using primary cultures of granulosa cells demon-
strate that inhibition of MAPK ERK1/2 decreased FSH-
induced progesterone secretion [14,30,35], 3βHSD [14]
and StAR expression [12,36]. MAPK ERK1/2 regulates tar-
get gene expression by activating downstream transcrip-
tion factors including the steroidogenic factor 1 (SF-1)
[36]. Furthermore, the 3βHSD type 2 promoter contains a
consensus sequence for SF-1 [37]. Thus, high concentra-
tions of glucose (5 or 10 g/l) like those we used may
reduce progesterone secretion in rat granulosa cells
through inhibition of MAPK ERK1/2 leading to a reduc-
tion in the 3βHSD and/or StAR levels and consequently
progesterone secretion. We can not also exclude that high
concentration of glucose may cause energy stress for the
cells and consequently a reduction of the steroid produc-
tion. However, we observed that high concentrations of
glucose did not affect AMPK activation. AMPK is consid-
ered to be a master switch in regulating glucose metabo-
lism: it acts as a fuel gauge, being activated in conditions
of extreme phosphate depletion and inhibited by high
levels of ATP [38]. In granulosa cells, glucose can be
metabolized through the pentose phosphate pathway and
this leads to the production of ATP [39]. Thus, high levels
of glucose should reduce AMPK phosphorylation. How-
ever, we can not exclude the possibility that glucose regu-
lates AMPK phosphorylation in rat granulosa cells but
only in conditions different to those we used (different
doses or after different periods of time). We recently
showed that AMPK activation decreases progesterone
secretion through MAPK ERK1/2 inhibition in rat granu-
losa cells. As 10 g/l glucose did not affect AMPK phospho-
rylation, it probably acts through another molecular
mechanism to inhibit MAPK ERK1/2 phosphorylation.
There is evidence that inhibition of MAPK ERK1/2 leads
not only to a decrease in progesterone secretion but also
an increase in the p450 aromatase expression and oestra-
diol production [12]. We report that 5 or 10 g/l glucose
decreased progesterone and oestradiol production, and it
is therefore likely that glucose uses a molecular mecha-
nism other than the inhibition of MAPK ERK1/2 to reduce
oestradiol production. We found that 5 or 10 g/l glucose
did not affect granulosa cell proliferation in the basal state
or in response to FSH or IGF-1. These observations are
opposite to findings for other cell types. For example,
Turner and Bierman [40] and Hehenberger and Hansson
[41] have stated that glucose was important for cell prolif-
eration; they report that increasing glucose levels to 18
and 15.5 mM (about 3 g/l), respectively, increases fibrob-
last proliferation, whereas further increases lead to an
inhibition of proliferation [40,41]. Thus, the effect of glu-
cose on cell proliferation seems to depend on the concen-
tration used and the cell type. We have shown that high
concentrations of glucose (10 g/l) did not affect the abun-
dance of adiponectin receptors in rat granulosa cells.
However, it is plausible that glucose modulates the signal-
ling pathways activated by adiponectin. We recently
observed that human recombinant adiponectin activated
several signalling pathways including AMPK, MAPK
ERK1/2 and p38, and also Akt [27]. Thus, the effects of
high glucose levels on the adiponectin response in rat
granulosa cells need to be tested.
We also investigated the effect of hyperglycaemia (about 4
g/l or 22 mM glucose) in vivo in the ovary of streptozo-
tocin-induced diabetic rats. As expected, the plasma con-
centrations of insulin were low in these STZ diabetic rats
and they also had lower plasma adiponectin and resistin
levels than rat controls. The concentration of adiponectin
in plasma is diminished in type 2 diabetes [42] whereas it
has been reported that the adiponectin concentration
increased in type 1 diabetic patients [43,44]. Our work
suggests that STZ rats may have a degree of insulin resist-
ance. We did not analyze the total body fat content. How-
ever, when we removed liver and muscle from STZ and
Control rats, STZ rats seemed to lose fat mass (data not
shown) despite their body weight not being significantly
different to controls (mean: 229 g versus 214 g p = 0.1).
The decreased fat mass may explain the diminished adi-
ponectin and resistin levels. We observed that plasma pro-
gesterone and oestradiol concentrations were lower in
STZ-treated rats than in controls suggesting that ovarian
steroidogenesis function was altered. The decline in ster-
oid production in several diabetic states is well docu-
mented [2,3,45,46]. However, the mechanism of the
reduction in ovarian steroidogenesis is not clear. In the
present study, no decrease in the amounts of 3βHSD and
p450 aromatase was observed whereas the levels of StAR
and p450scc proteins were increased in the ovaries of STZ-
treated animals. These data are in a good agreement withReproductive Biology and Endocrinology 2008, 6:11 http://www.rbej.com/content/6/1/11
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other studies that report no alteration to p450scc or
3βHSD [47]. Possibly, the activity of these key steroido-
genesis enzymes is decreased in STZ-treated rats and this
could explain the decline in steroid production in these
animals. We found that the protein level of adiponectin
receptors (AdipoR1/R2) was similar both in ovaries and
in the liver of control and STZ-treated rats. Only the
AdipoR2 protein was slightly less abundant in muscle of
STZ-treated than control rats. Several studies have
explored the mRNA for adiponectin receptors in diabetic
human and animal tissues, and the results are the subject
of debate. They depend on the body mass index, the level
of insulin resistance and especially the tissue type. In
human and rodent type 2 diabetic model, mRNAs for
insulin and the AdipoR1/R2 are altered in muscle and
liver [18,48]. Another group concluded that the adiponec-
tin level is inversely correlated with obesity, diabetes and
insulin resistance, whereas the amounts of adipoR1/R2
mRNA increased in muscle in a compensatory effect [28].
In contrast, Hammarstedt's group and Yao's group
reported no change in the expression of the two adiponec-
tin receptors in type 2 diabetic patients and rodents
[29,49]. In the present study, we observed higher levels of
AMPK phosphorylation in the ovary and also in muscle of
STZ-treated than control rats. AMPK is activated by energy
stress, for example glucose deprivation [50]. In our model,
STZ treatment causes a lack of insulin because of the pan-
creatic function impairment. Thus, hyperglycaemia devel-
ops but no glucose can enter into the cell of the insulin
target tissues. This cellular stress may involve AMPK acti-
vation in the various tissues explored including the ovary
despite it not being considered to be a major insulin-
dependent tissue. The increase in AMPK activation in the
ovary of STZ-treated rats may contribute to the decrease in
progesterone secretion in these animals. Indeed, we have
recently shown that AMPK activation decreases progester-
one secretion in rat granulosa cells [14].
Conclusion
Our various results suggest that high levels of glucose (5
or 10 g/l) decrease steroid production. However, the
mechanisms involved in the reduction in ovarian ster-
oidogenesis depend on the model used (in vitro primary
rat granulosa cells or in vivo ovary of STZ-treated rat). In
rat granulosa cells, high levels of glucose decrease the pro-
tein levels of the main steroidogenesis factors whereas the
amounts of these factors are not affected or even increased
in the ovaries of STZ-treated rats. Furthermore, high levels
of glucose did not affect the abundance of adiponectin
receptors in vitro in rat granulosa cells or in vivo in the
ovaries of STZ-treated rats.
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